ActinexRX Pharmaceuticals

Actinex is a late stage pharmaceutical company that has developed a patented topical cream for the treatment of keratinocyte carcinomas (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The company is selling these treatments over the counter with plans on conducting a Phase 2 fast track clinical trial. The Problem The most common treatments for cutaneous KCs are surgical interventions to remove the lesion, including excisional surgery and Mohs surgery. Although these treatments have high cure rates, they result in physical and emotional scars. Additional treatments such as electrodessication, radiation therapy, cryosurgery and photodynamic therapy, aim to destroy the tumor tissue in superficial lesions. These methods can result in pain, swelling, and scarring. Overall, these treatments can result in disfigurement that adversely impacts patients’ quality of life. Oral (systemic) treatments are generally only considered for patients with more advanced BCC and SCC. The Solution Actinex treats Cutaneous Squamous, Basal Cell, Actinic Keratosis skin cancer with a patented topical treatment that is 80-90% effective. The treatment solves the most significant skin cancer issues, Surgery, Scars, Recovery Time and is Less Expensive. Another significant issue is pre cancerous conditions which Actinex is the only product on the market today that treats precancerous conditions saving significant amounts of pain and suffering by stopping the condition from evolving into cancer. Actinex has treated over 5,000 patients to date.